NL-OMON21505
Completed
Phase 3
The INVEST study Treatment in advanced Parkinson’s disease: continuous intrajejunal levodopa INfusion VErsus deep brain STimulation.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- <p>advanced Parkinson's disease, gevorderde ziekte van Parkinson</p>
- Sponsor
- ZonMw
- Enrollment
- 66
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;
- •\- Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia;
Exclusion Criteria
- •\- Age below 18 years
- •\- Previous PD\-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical observation on the treatment of Parkinson's disease with fatigue by three injectionsParkinson's disease fatigueITMCTR2200006777The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Not yet recruiting
Phase 1
A Clinical Study for the Treatment of Parkinson's Disease with Integrated Shi Shi Tonifying Kidney Pill and Xingnao Kaiqiao AcupunctureParkinson's diseaseITMCTR1900002280ShenZhen JinFangZhenLue Technology Ltd. Co.
Completed
Not Applicable
Treatment in advanced Parkinson*s disease: continuous intrajejunal levodopa infusion versus deep brain stimulation; a feasibility studyParkinson's DiseaseParkinson10028037NL-OMON39084Academisch Medisch Centrum59
Not yet recruiting
Not Applicable
A Clinical study of Parkinsonâ??s disease and comparativr evaluation of two unani formulations (Combination of jadwar and ood e saleeb with majoon e jograj gogul) in its management.Health Condition 1: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhereHealth Condition 2: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhereCTRI/2021/09/036722Department of Moalejat
Completed
Not Applicable
Early treatment of idiopathic Parkinson's disease with dopaminergic agonist piribedil in monotherapy. A two-year randomised, parallel, placebo-controlled study in idiopathic Parkinsonian de novo patientsISRCTN36646813Institut de Recherches Internationales Servier (France)400